Pegylated IFNα2a (PEG-IFNα2a) or PEG-IFNα2b in combination with ribavirin is currently standard treatment for patients with chronic hepatitis C (HCV) and compensated liver disease [32]. Here, IFNA2 is linked to chronic hepatitis C virus infection.